2026 sales of 1 trillion won and operating profit of 200 billion won
CEO Jang Doo-hyun “Profitability improvement performance of reorganization focusing on growth items”
Boryeong announced on February 6 that it is posting sales of 760.5 billion won and operating profit of 56.6 billion won in 2022. Compared to the previous year, sales increased by 21% and operating profit by 37%. It has exceeded target sales and operating profit with new records since inception.
Boryeong CEO Jang Doo-hyun said, “We reorganized our drug portfolio focusing on growth items and focusing on improving profitability through marketing efficiency.”
Last year, Boryeong caught two rabbits in terms of external appearance and profitability. The sales trend based on separate financial statements was KRW 170.6 billion in the first quarter, KRW 172.2 billion in the second quarter, KRW 187.7 billion in the third quarter, and KRW 191.6 billion in the fourth quarter.
With this record this year, it is possible to continue the title of highest performance ever held every year for 17 years since 2005. Operating profit also increased by 20.2% from last year, updating quarterly performance.
The Kanarb family, a new drug for high blood pressure, which is the leading product, recorded sales of 130.2 billion won based on a series of six products, including one Kanarb drug (ingredient: Fimasartan). This is an increase of 19% on the previous year. With the launch of Ducarb Plus (ingredient: Fimasartan + Amlodipine + Hydrochlorothiazide), a three-drug combination drug for high blood pressure last year, the Kanarb family is expected to see further growth this year.
Anti-cancer drugs also recorded sales of KRW 160.6 billion, a rapid growth of 61%. The neutropenia treatment Grassin (ingredient: filgrastim) and Nurastar (ingredient: pegfilgrastim), which began sales jointly with Kyowa Kirin Korea, recorded sales of 17.6 billion won and 34.6 billion won, respectively.
Biosimilars Samsung Bioepis Samphenet (ingredient: Trastuzumab) and OnbevG (ingredient: bevacizumab), which Boryung has sold exclusively since 2021, have also grown significantly.
Samphenet recorded sales of 7.2 billion won last year, an increase of 157% from the previous year. Onbevji recorded sales of 19.3 billion won last year, a whopping 421% increase from the previous year.
The CNS (central nervous system) sector also recorded sales of 26.6 billion won last year, focusing on Zyprexa (ingredient: olanzapine). This is a massive 127% increase compared to 2021.
Renal (kidney disease) recorded sales of 55.2 billion won last year, up 7.8% from the previous year. In the cargo area, it recorded sales of 59.9 billion won, up 52% from the previous year.
The over-the-counter drug Yonggaksan recorded sales of 13 billion won, up 38% from the previous year due to the COVID-19 crisis.
Boryeong has been leading a bold innovation with 2022 as the ‘first year of innovation and change’ with CEO Jang Doo-hyun at the center. It focused on improving profitability by strengthening its own product capabilities, reorganizing its drug portfolio focusing on growth items, and improving sales marketing efficiency.
Copyright © Uihyup Newspaper Unauthorized reproduction and redistribution prohibited